R&D
Table 1: New product approvals in the EU*
Product Generic name Company Indication Date
Torisel temsirolimus Wyeth advanced renal cell carcinoma 19/11/07
Tasigna nilotinib Novartis chronic myelogenous leukaemia 19/11/07
Vectibix panitumumab Amgen colorectal cancer 3/12/07
Nevanac nepafenac Alcon post-operative pain and inf_l ammation 11/12/07
Glubrava pioglitazone/ Takeda type 2 diabetes 11/12/07
metformin
Atripla efavirenz/ emtricitabine/ Bristol-Myers HIV infection 13/12/07
tenofovir disoproxil Squibb/Gilead Sciences
Isentress raltegravir Merck Sharp & Dohme HIV infection (in combination) 20/12/07
Tesavel sitagliptin Merck Sharp & Dohme type 2 diabetes (in combination) 10/1/08
Ivemend fosaprepitant dimeglumine Merck Sharp & Dohme nausea and vomiting in cancer 11/1/08
chemotherapy
Pradaxa dabigatran etexilate mesilate Boehringer Ingelheim primary prevention of venous 18/3/08
thrombo-embolic events
Ef_f entora fentanyl citrate Cephalon breakthrough pain in adults with cancer 4/4/08
Volibris ambrisentan GlaxoSmithKline pulmonary arterial hypertension 21/4/08
Mycamine micafungin Astellas Pharma candidiasis 25/4/08
Prepandrix H5N1 vaccine GSK Biologicals pre-pandemic f_l u vaccine 14/5/08
Pandemrix H5N1 vaccine GSK Biologicals pandemic f_l u vaccine 20/5/08
Adenuric febuxostat Beaufour Ipsen chronic hyper-uricaemia 28/5/08
Relistor methylnaltrexone bromide Wyeth Europa opioid-induced constipation 2/7/08
Trevaclyn/ nicotinic acid/ laropiprant Merck Sharp & Dohme dyslipidaemia 3/7/08
Tredaptive/ Pelzont
Latixa ranolazine CV Therapeutics angina 9/7/08
Firazyr icatibant Jerini hereditary angioedema 11/7/08
Janumet/ sitagliptin/metformin Merck Sharp & Dohme type 2 diabetes 16/7/08
Velmetia/ Ef_f_i cib
Bridion sugammadex Organon reversal of drug-induced 25/7/08
neuromuscular blockade
Doribax doripenem Janssen-Cilag infections 25/7/08
Intelence etravirine Janssen-Cilag HIV infection 28/8/08
Vimpat lacosamide UCB epileptic partial-onset seizures 29/8/08
Xarelto rivaroxaban Bayer HealthCare prevention of venous thrombo-embolism 30/9/08
Evicel human f_i brinogen/ Omrix supportive therapy to improve 6/10/08
human thrombin haemostasis in surgery
Ceplene histamine dihydrochloride EpiCept acute myeloid leukaemia 7/10/08
*from November 2007 to October 31st, 2008
www.scripnews.com/supplements Scrip 100
49
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128